Friday, October 21, 2016 10:03:01 AM
You/we can only take these one step at a time. This was HUGE in the process.
As far as what I think as to why HC did approve much earlier than expected: There's very high credibility within the team that RW has assembled across the multiple elements linked together to get this to a Ph1-b trial. I think that lead HC to conclude that there is very little risk to the procedures based on PMCC participation, and the medical team experience and reputations that's been assembled
I do think that the pps will reflect the milestone. I don't think the "word" is out yet and we will see pps appreciation of 10%-20%. I think that's a low estimate/guess, but I try to estimate low regardless. If it goes higher I'm happy to be wrong.
I think that once the financing is done, there will be other lab rat tests to move the PDC across multiple cancers as quickly as possible. Only funding is holding back the research and testing.
The more data and research, the more exposure and pps appreciation. IMO.
Regards,
BK
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM